Pharmaceuticals Biotechnology and Life Sciences
More
-
PARSIPPANY, N.J.-- Actavis Inc. said Friday a federal appeals court granted an injection that blocks it from selling a generic version of AstraZeneca PLC's asthma treatment Pulmicort Respules.
-
BUFFALO, N.Y.-- Drug-maker ISTA Pharmaceuticals has pleaded guilty in a federal case involving its eye drug Xibrom. The Justice Department says the case was settled in U.S. District Court in Buffalo Friday. ISTA, which was acquired by Rochester- based Bausch& Lomb last year, admits to promoting Xibrom for uses beyond what the Food and Drug Administration approved.
-
BUFFALO, N.Y.-- Drug-maker ISTA Pharmaceuticals has pleaded guilty in a federal case involving its eye drug Xibrom. The Justice Department says the case was settled in U.S. District Court in Buffalo Friday. ISTA, which was acquired by Rochester- based Bausch& Lomb last year, admits to promoting Xibrom for uses beyond what the Food and Drug Administration approved.
-
The New York- based company said it was cooperating with the request in the May 6 subpoena. A spokeswoman for the U.S. Attorney's Office in New York also declined to comment. Attorney for the Southern District of New York, was noted briefly in the company's annual 10- k filing with the Securities and Exchange Commission.
-
NEW YORK, May 24- Canada's Valeant Pharmaceuticals International is nearing a deal to acquire eye care company Bausch& Lomb Holdings Inc from Warburg Pincus LLC for about $9 billion, a person familiar with the matter said on Friday.
-
NEW YORK-- Royalty Pharma disclosed Friday that a negligible number of Elan Corp. PLC shareholders have voted their shares in favor of its offer to buy the company. The New York company offered to buy Elan in February for $11 per share and later raised the offer to $11.25 per share.
-
*Novo shares up 0.7 percent, outperforming sector. COPENHAGEN, May 24- Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.
-
Markey's proposal differs from legislation approved by a Senate committee on Wednesday that would give the FDA oversight only over compounding pharmacies that make sterile products and ship them across state lines.
-
WASHINGTON-- The Food and Drug Administration said Thursday it approved a new blood test from Roche to help doctors diagnose diabetes. The FDA said Roche's test is the first to be approved to diagnose the disease.
-
SEATTLE-- Omeros Corp. said Thursday it will start two midstage clinical trials of its drug OMS824 later this year, giving its stock a boost. Omeros said Thursday that the Food and Drug Administration awarded OMS824 orphan drug status as a treatment for Huntington's.
-
SAN DIEGO-- Biopharmaceutical company Halozyme Therapeutics Inc. said Thursday that it has named David Ramsay as chief financial officer, replacing Kurt Gustafson. Gustafson had been an executive at Amgen Inc. before he joined Halozyme in 2009. Halozyme said he was leaving the company to pursue other opportunities.
-
CHICAGO, May 23- Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.
-
*FDA panel says suvorexant safe, effective at lower doses. On Monday, the FDA's internal reviewers published a report expressing concern about suvorexant's potential to cause next-day sleepiness and impaired driving.
-
NEW YORK-- Shares of Regeneron Pharmaceuticals Inc. edged higher on Wednesday on positive clinical trial data for an experimental asthma drug. THE SPARK: The New England Journal of Medicine's website on Tuesday published the results of a study of the asthma treatment dupilumab, which Regeneron is developing with French drugmaker Sanofi.
-
NEW YORK, May 22- Little known biotechnology company Merrimack Pharmaceuticals Inc has quietly built a large pipeline of experimental cancer treatments that it aims to deliver at a fraction of the cost spent by larger rivals. Medicare system contending with new cancer treatments that can exceed $100,000 per patient.
-
TRENTON, N.J.-- Drugmaker Pfizer Inc. plans to try to sell its controlling stake in its former animal health business, Zoetis Inc., through a voluntary stock exchange with Pfizer shareholders.
-
"The market for biotech isn't screaming hot, and it's not like everyone can get deals done, but we're seeing attractive returns being generated," said Bob Carey, a managing director at JMP Securities who works with biotech companies. "
-
Bristol-Myers Squibb could be a big winner with a portfolio of cancer treatments under development that use a patient's own immune system to attack the disease, according to a Citi, which raised its rating on the drugmaker.
-
May 22- Pfizer Inc said on Wednesday that it would unwind its remaining stake in animal health business Zoetis Inc through an exchange offer in which shareholders can swap Pfizer stock for that of Zoetis at a discount. Giant pharmaceutical maker Pfizer spun off Zoetis shares in an initial public offering in February that raised $2.2 billion.
-
Merck inked a $5 billion share repurchase agreement with Goldman Sachs, as the drug giant looks to prop up shareholder value in face of competition from generics makers.